USRE33364EExpiredUtility
Non-aromatic oxygenated strong acid dehydration of 9α-hydroxyandrostenediones
Priority: Apr 11, 1977Filed: Apr 14, 1988Granted: Oct 2, 1990
Est. expiryApr 11, 1997(expired)· nominal 20-yr term from priority
C07J 1/0011
2
PatentIndex Score
0
Cited by
1
References
9
Claims
Abstract
The present invention discloses a process for the production of androsta-4,9(11)-diene-3,17-dione type compounds from 9α-hydroxyandrostenedione type compounds by non-aromatic oxygenated strong acid dehydration.
Claims
exact text as granted — not AI-modifiedWe claim:
1. A process for the preparation of a steroid of the formula: ##STR6## where R 6 is a hydrogen or fluorine atom, or a methyl group; R 16 is a hydrogen atom or methyl group and where ˜ indicates that the attachment of the R 6 and R 16 groups are in the α or β configuration which comprises reacting a 9α-hydroxy steroid of the formula: ##STR7## where R 6 , R 16 , and ˜are defined above with a nonaromatic oxygenated acid with a pK.sub.α of less than or equal to 1.0.
2. A process according to claim 1 where the acid is selected from the group consisting of chlorosulfonic, sulfuric, .[.phosphoric,.]. methanesulfonic, perchloric and trifluoroacetic.
3. A process according to claim 2 where 0.8-5 equivalents of chlorosulfonic acid is present, sulfuric acid is present at a concentration of 60-100%, .[.phosphoric acid and.]. methanesulfonic acid are present at a concentration of 70-100%, perchloric acid is present at a concentration of 5-70% and trifluoroacetic acid is present at a concentration of 70-100%.
4. A process according to claim 3 where 2-3 equivalents of chlorosulfonic acid is present, sulfuric acid is present at a concentration of 70-96%, .[.phosphoric acid and.]. methane-sulfonic acid are present at a concentration of 80-90%, perchloric acid is present at a concentration of 20-40%, and trifluoroacetic acid is present at a concentration of 75-95%.
5. A process according to claim 4 where the steroid (I) is 9α-hydroxyandrostenedione.
6. A process according to claim 2 where the acid is chlorosulfonic acid.
7. A process according to claim 6 where 0.8-5 equivalents of chlorosulfonic acid are present.
8. A process according to claim 2 where the acid is sulfuric acid.
9. A process according to claim 8 where the sulfuric acid is present at a concentration of 60-100%. .[.10. A process according to claim 2 where the acid is phosphoric acid..]. .[.11. A process according to claim 10 where
the phosphoric acid is present at a concentration of 70-100%..]. 12. A
process according to claim 2 where the acid is methanesulfonic acid. 13. A process according to claim 12 where the methanesulfonic acid is present at
a concentration of 70-100%. 14. A process for the preparation of androsta-4,9(11)-diene-3,17-dione which comprises reacting
9α-hydroxyandrostenedione with chlorosulfonic acid. 15. A process according to claim 14 where 0.8-5 equivalents of chlorosulfonic acid are
present. 16. A process according to claim 15 where 2-3 equivalents of
chlorosulfonic acid are present. 17. A process for the preparation of androsta-4,9(11)-diene-3,17-dione which comprises reacting
9α-hydroxyandrostenedione with sulfuric acid. 18. A process according to claim 17 where the sulfuric acid is present at a
concentration of 60-100%. 19. A process according to claim 18 where the
sulfuric acid is present at a concentration of 70-96%. 20. A process for the preparation of androsta-4,9(11)-diene-3,17-dione which comprises
reacting 9α-hydroxyandrostenedione with phosphoric acid. 21. A process according to claim 20 where the phosphoric acid is present at a
concentration of 70-100%. 22. A process according to claim 21 where the
phosphoric acid is present at a concentration of 80-90%. 23. A process for the preparation of androsta-4,9(11)-diene-3,17-dione which comprises
reacting 9α-hydroxyandrostenedione with methanesulfonic acid. 24. A process according to claim 23 where the methanesulfonic acid is present at
a concentration of 70-100%. 25. A process according to claim 24 where the methanesulfonic acid is present at a concentration of 80-90%.Join the waitlist — get patent alerts
Track USRE33364E — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.